enow.com Web Search

  1. Ad

    related to: lhrh agonist breast cancer life expectancy

Search results

  1. Results from the WOW.Com Content Network
  2. Gonadotropin-releasing hormone modulator - Wikipedia

    en.wikipedia.org/wiki/Gonadotropin-releasing...

    A GnRH modulator, or GnRH receptor modulator, also known as an LHRH modulator or LHRH receptor modulator, is a type of medication which modulates the GnRH receptor, the biological target of the hypothalamic hormone gonadotropin-releasing hormone (GnRH; also known as luteinizing-releasing hormone, or LHRH).

  3. Zoptarelin doxorubicin - Wikipedia

    en.wikipedia.org/wiki/Zoptarelin_doxorubicin

    The LHRH receptor is aberrantly present on the cell surface of approximately 80% of endometrial and ovarian cancers, 86% of prostate cancers and about 50% of breast cancers. Whereas in normal tissues, expression of this receptor is mainly confined to the pituitary gland, reproductive organs and hematopoietic stem cells.

  4. Leuprorelin - Wikipedia

    en.wikipedia.org/wiki/Leuprorelin

    Leuprorelin, also known as leuprolide, is a manufactured version of a hormone used to treat prostate cancer, breast cancer, endometriosis, uterine fibroids, for early puberty, or as part of transgender hormone therapy. [10] [11] It is given by injection into a muscle or under the skin. [10]

  5. Gonadotropin-releasing hormone agonist - Wikipedia

    en.wikipedia.org/wiki/Gonadotropin-releasing...

    A gonadotropin-releasing hormone agonist (GnRH agonist) is a type of medication which affects gonadotropins and sex hormones. [1] They are used for a variety of indications including in fertility medicine and to lower sex hormone levels in the treatment of hormone-sensitive cancers such as prostate cancer and breast cancer, certain gynecological disorders like heavy periods and endometriosis ...

  6. Cancer survival rates - Wikipedia

    en.wikipedia.org/wiki/Cancer_survival_rates

    The American Cancer Society reports 5-year relative survival rates of over 70% for women with stage 0-III breast cancer with a 5-year relative survival rate close to 100% for women with stage 0 or stage I breast cancer. The 5-year relative survival rate drops to 22% for women with stage IV breast cancer. [3]

  7. Column: A cancer survivor's advice: research, persistence and ...

    www.aol.com/news/column-cancer-survivors-advice...

    The cancer was gone. Two months later, she had another test. No cancer. “Her cancer is, at this moment, undetectable and in remission. For anaplastic cancer that’s very unusual,” Dr. Mita ...

  8. Goserelin - Wikipedia

    en.wikipedia.org/wiki/Goserelin

    Goserelin, sold under the brand name Zoladex among others, is a medication which is used to suppress production of the sex hormones (testosterone and estrogen), particularly in the treatment of breast cancer and prostate cancer. [2] [3] It is an injectable gonadotropin releasing hormone agonist (GnRH agonist). Structurally, it is a decapeptide.

  9. Gonadotropin-releasing hormone - Wikipedia

    en.wikipedia.org/wiki/Gonadotropin-releasing_hormone

    2796 14714 Ensembl ENSG00000147437 ENSMUSG00000015812 UniProt P01148 P13562 RefSeq (mRNA) NM_001083111 NM_000825 NM_008145 RefSeq (protein) NP_000816 NP_001076580 NP_032171 Location (UCSC) Chr 8: 25.42 – 25.42 Mb Chr 14: 67.98 – 67.99 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse Gonadotropin-releasing hormone (GnRH) is a releasing hormone responsible for the release of ...

  1. Ad

    related to: lhrh agonist breast cancer life expectancy